Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manu Prasad

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Cancers|June 2, 2021
IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck CancerMai Badarni, Manu Prasad, Artemiy Golden, et al.
International Journal of Cancer|May 14, 2019
The long noncoding RNA TP73-AS1 promotes tumorigenicity of medulloblastoma cellsMor Varon, Tal Levy, Gal Mazor, et al.
Molecular Oncology|July 28, 2023
Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancerOfra Novoplansky, Avital B Shnerb, Divyasree Marripati, et al.
Nature Genetics|June 2, 2025
Longitudinal and multisite sampling reveals mutational and copy number evolution in tumors during metastatic disseminationKarena Zhao, Joris Vos, Stanley Lam, et al.
Neoplasia (New York, N.Y.)|March 21, 2025
Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancersDinesh Babu Manikandan, Sankar Jagadeeshan, Sooraj Mathukkada, et al.
Cancer Research|February 8, 2023
Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck CancerSankar Jagadeeshan, Manu Prasad, Mai Badarni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2026
Genomic enrichment and functional impact of TP53 and CYLD alterations in recurrent and metastatic HPV-associated head and neck cancerManu Prasad, Alex T Cheng, Marcel Mayer, et al.
Journal for Immunotherapy of Cancer|March 16, 2022
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancerManu Prasad, Jonathan Zorea, Sankar Jagadeeshan, et al.
Nature Medicine|August 24, 2023
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trialJoris L Vos, Bharat Burman, Swati Jain, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Cancers|June 2, 2021
IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck CancerMai Badarni, Manu Prasad, Artemiy Golden, et al.
International Journal of Cancer|May 14, 2019
The long noncoding RNA TP73-AS1 promotes tumorigenicity of medulloblastoma cellsMor Varon, Tal Levy, Gal Mazor, et al.
Molecular Oncology|July 28, 2023
Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancerOfra Novoplansky, Avital B Shnerb, Divyasree Marripati, et al.
Nature Genetics|June 2, 2025
Longitudinal and multisite sampling reveals mutational and copy number evolution in tumors during metastatic disseminationKarena Zhao, Joris Vos, Stanley Lam, et al.
Neoplasia (New York, N.Y.)|March 21, 2025
Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancersDinesh Babu Manikandan, Sankar Jagadeeshan, Sooraj Mathukkada, et al.
Cancer Research|February 8, 2023
Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck CancerSankar Jagadeeshan, Manu Prasad, Mai Badarni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2026
Genomic enrichment and functional impact of TP53 and CYLD alterations in recurrent and metastatic HPV-associated head and neck cancerManu Prasad, Alex T Cheng, Marcel Mayer, et al.
Journal for Immunotherapy of Cancer|March 16, 2022
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancerManu Prasad, Jonathan Zorea, Sankar Jagadeeshan, et al.
Nature Medicine|August 24, 2023
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trialJoris L Vos, Bharat Burman, Swati Jain, et al.
Pageof 3